Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 05:11pm CET

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Purchased Brazil drugstore chain Drogaria Onofre last week

(Updates with details about an acquisition and other comments made during a conference call, beginning in the seventh paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

In a conference call with analysts, CVS disclosed it purchased Brazil drugstore chain Drogaria Onofre last week, though no price tag was disclosed as CVS called the deal "not financially material."

CVS will acquire 44 locations through the deal, the company's first acquisition abroad. The purchase comes more than six months after Walgreen agreed to spend $6.7 billion to buy a 45% stake in European pharmacy operator Alliance Boots.

CVS said it views Brazil as an attractive market, saying that region's health-care and pharmacy segments should grow in double digits for the next decade.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Walgreen has sought to strengthen its core business with its new loyalty-card program and by selling more private-label offerings. CVS on Wednesday indicated it is staying focused on retaining customer loyalty by launching more targeted promotions and e-mail offers.

CVS last week launched a pharmacy rewards program to promote retention and better prescription adherence. CVS has also doubled the amount of e-mails it sends and is seeing greater interest in the beauty-product deals it offers. Overall, CVS posted a 19% jump in the amount of offers redeemed by consumers last year.

CVS shares were down 0.2% to $51.61 in recent trading. The stock is up 6.7% in 2013.

 
  --Tess Stynes contributed to this article 

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Valeurs citées dans l'article
ChangeLast1st jan.
CVS HEALTH -1.72% 70.66 Delayed Quote.-3.74%
EXPRESS SCRIPTS HOLDING CO 1.09% 76.05 Delayed Quote.-0.76%
RITE AID CORPORATION 3.29% 2.2 Delayed Quote.4.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
02/20Albertsons to buy Rite Aid as Amazon threat looms
RE
02/20CVS HEALTH : Fast Company Recognizes CVS Health on 2018 World's Most Innovative ..
PR
02/15CVS HEALTH : Management's Discussion and Analysis of Financial Condition and Res..
AQ
02/14CVS HEALTH : increasing starting pay to $11 an hour
AQ
02/12CVS HEALTH : latest to boost pay, programs thanks to federal tax reform
AQ
02/10CVS HEALTH : Salisbury town center CVS sold for $7.9 million
AQ
02/10CVS HEALTH : CEO Reveals How It Will Benefit From Tax Reform
AQ
02/09CVS HEALTH CORP : Other Events (form 8-K)
AQ
02/09CVS HEALTH : to Raise Starting Wage -- WSJ
DJ
02/08CVS HEALTH : New CVS Health Poll Reveals That A Majority of U.S. Women Are Unawa..
AQ
More news
News from SeekingAlpha
02/20Healthcare Innovation Or Exacerbating The Crisis? 
02/19Healthcare In Transition 
02/15The MnM Portfolio - Checking In On Portfolio Fundamentals 
02/14ROAD TO FINANCIAL INDEPENDENCE : My January 88-Stock Portfolio Review 
02/14My Dividend Achievers Finally Pass The Index 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 905 M
Net income 2018 5 788 M
Debt 2018 20 395 M
Yield 2018 3,01%
P/E ratio 2018 12,80
P/E ratio 2019 11,75
EV / Sales 2018 0,49x
EV / Sales 2019 0,46x
Capitalization 72 834 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 88,1 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-3.74%72 834
WALGREENS BOOTS ALLIANCE-5.69%70 258
EXPRESS SCRIPTS HOLDING CO-0.76%42 608
MCKESSON CORPORATION-4.60%31 375
AMERISOURCEBERGEN4.99%21 835
CARDINAL HEALTH9.91%21 822